Literature DB >> 31941713

Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents.

Matthew E Klein1,2,3, Joshua Chandra2,3, Salma Sheriff2,3, Roberto Malinow4,3.   

Abstract

Slow response to the standard treatment for depression increases suffering and risk of suicide. Ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, can rapidly alleviate depressive symptoms and reduce suicidality, possibly by decreasing hyperactivity in the lateral habenula (LHb) brain nucleus. Here we find that in a rat model of human depression, opioid antagonists abolish the ability of ketamine to reduce the depression-like behavioral and LHb hyperactive cellular phenotypes. However, activation of opiate receptors alone is not sufficient to produce ketamine-like effects, nor does ketamine mimic the hedonic effects of an opiate, indicating that the opioid system does not mediate the actions of ketamine but rather is permissive. Thus, ketamine does not act as an opiate but its effects require both NMDA and opiate receptor signaling, suggesting that interactions between these two neurotransmitter systems are necessary to achieve an antidepressant effect.

Entities:  

Keywords:  ketamine; lateral habenula; opioid system

Mesh:

Substances:

Year:  2020        PMID: 31941713      PMCID: PMC7007545          DOI: 10.1073/pnas.1916570117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  68 in total

1.  Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors.

Authors:  O Hustveit; A Maurset; I Oye
Journal:  Pharmacol Toxicol       Date:  1995-12

Review 2.  How do antidepressants work? New perspectives for refining future treatment approaches.

Authors:  Catherine J Harmer; Ronald S Duman; Philip J Cowen
Journal:  Lancet Psychiatry       Date:  2017-01-31       Impact factor: 27.083

3.  Pharmacological inhibition of the lateral habenula improves depressive-like behavior in an animal model of treatment resistant depression.

Authors:  C Winter; B Vollmayr; A Djodari-Irani; J Klein; A Sartorius
Journal:  Behav Brain Res       Date:  2010-08-03       Impact factor: 3.332

4.  Stress transforms lateral habenula reward responses into punishment signals.

Authors:  Steven J Shabel; Chenyu Wang; Bradley Monk; Sage Aronson; Roberto Malinow
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-31       Impact factor: 11.205

5.  Specificity of the learned helplessness model of depression.

Authors:  A D Sherman; J L Sacquitne; F Petty
Journal:  Pharmacol Biochem Behav       Date:  1982-03       Impact factor: 3.533

6.  mu-Opioid receptors modulate NMDA receptor-mediated responses in nucleus accumbens neurons.

Authors:  G Martin; Z Nie; G R Siggins
Journal:  J Neurosci       Date:  1997-01-01       Impact factor: 6.167

Review 7.  Psychotherapeutic benefits of opioid agonist therapy.

Authors:  Peter L Tenore
Journal:  J Addict Dis       Date:  2008

Review 8.  Translating the Habenula-From Rodents to Humans.

Authors:  Laura-Joy Boulos; Emmanuel Darcq; Brigitte Lina Kieffer
Journal:  Biol Psychiatry       Date:  2016-06-07       Impact factor: 13.382

9.  Comparative pharmacology of the optical isomers of ketamine in mice.

Authors:  S Ryder; W L Way; A J Trevor
Journal:  Eur J Pharmacol       Date:  1978-05-01       Impact factor: 4.432

Review 10.  Opioid receptors: distinct roles in mood disorders.

Authors:  Pierre-Eric Lutz; Brigitte L Kieffer
Journal:  Trends Neurosci       Date:  2012-12-06       Impact factor: 13.837

View more
  23 in total

Review 1.  Ketamine: Leading us into the future for development of antidepressants.

Authors:  Flavia R Carreno; Daniel J Lodge; Alan Frazer
Journal:  Behav Brain Res       Date:  2020-02-02       Impact factor: 3.332

2.  Reply to Hashimoto: Ketamine is not an opioid but requires opioid system for antidepressant actions.

Authors:  Roberto Malinow; Matthew E Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-19       Impact factor: 11.205

3.  Are NMDA and opioid receptors involved in the antidepressant actions of ketamine?

Authors:  Kenji Hashimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-19       Impact factor: 11.205

4.  Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors.

Authors:  Hildegard A Wulf; Caroline A Browne; Carlos A Zarate; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2022-04-23       Impact factor: 4.530

5.  Response to intravenous racemic ketamine after switch from intranasal (S)-ketamine on symptoms of treatment-resistant depression and post-traumatic stress disorder in Veterans: A retrospective case series.

Authors:  Sean Bentley; Hewa Artin; Eamonn Mehaffey; Fred Liu; Kevin Sojourner; Andrew Bismark; David Printz; Ellen E Lee; Brian Martis; Sharon De Peralta; Dewleen G Baker; Jyoti Mishra; Dhakshin Ramanathan
Journal:  Pharmacotherapy       Date:  2022-02-24       Impact factor: 4.705

Review 6.  Mechanisms of ketamine and its metabolites as antidepressants.

Authors:  Evan M Hess; Lace M Riggs; Michael Michaelides; Todd D Gould
Journal:  Biochem Pharmacol       Date:  2021-12-27       Impact factor: 5.858

7.  Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series.

Authors:  Hewa Artin; Sean Bentley; Eamonn Mehaffey; Fred X Liu; Kevin Sojourner; Andrew W Bismark; David Printz; Ellen E Lee; Brian Martis; Sharon De Peralta; Dewleen G Baker; Jyoti Mishra; Dhakshin Ramanathan
Journal:  EClinicalMedicine       Date:  2022-05-06

8.  Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression.

Authors:  Ana Maria Rivas-Grajales; Ramiro Salas; Meghan E Robinson; Karen Qi; James W Murrough; Sanjay J Mathew
Journal:  Int J Neuropsychopharmacol       Date:  2021-05-18       Impact factor: 5.176

Review 9.  Cognitive effects of rapid-acting treatments for resistant depression: Just adverse, or contributing to clinical efficacy?

Authors:  Salvador M Guinjoan; Karl-Jürgen Bär; Joan A Camprodon
Journal:  J Psychiatr Res       Date:  2021-06-15       Impact factor: 5.250

10.  Determination of Diffusion Kinetics of Ketamine in Brain Tissue: Implications for in vitro Mechanistic Studies of Drug Actions.

Authors:  Zachary Geiger; Brett VanVeller; Zarin Lopez; Abdel K Harrata; Kathryn Battani; Lauren Wegman-Points; Li-Lian Yuan
Journal:  Front Neurosci       Date:  2021-07-01       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.